Multi-drug resistance with non-chemotherapy agents in colorectal cancer
Speaker: Chris Farrell
Affiliation: Professor, Healthcare Genetics and Genomics School of Nursing Clemson University Adjunct Professor at Manchester University
Event Details:
Dr. Christopher Farrell is an assistant professor in the Healthcare Genetics and Genomics (HCG) program at Clemson University. Prior to joining Clemson University, he started his career in the pharmaceutical industry where he worked for two different biotechnology companies over a seven year period. The companies were the Immune Response Corporation and Centocor, which is a sub-company of the Johnson and Johnson Company. In the pharmaceutical industry, he worked in the field of biological therapeutics such as monoclonal antibodies and viral vaccine-based therapies. He then entered the graduate school at the University of South Carolina in the School of Medicine and earned his PhD in the Biomedical Sciences. As a post-doctoral fellow at SC Cancer Center and Medical College of Georgia Cancer Center, he identified several novel cancer genes in colorectal and breast tumors. In 2009, he started teaching in healthcare programs in pharmacy, medical, and nursing. At Clemson University, his area of research is focused on cancer genetics, cancer education in rural communities, pharmacogenomics education and the study of inherited disorders such as Aarskog-Scott and Fraser syndromes.
The Spring 2024 Series will be in-person (in MUFW 136) and/or live-streamed. All sessions will be recorded. To access a recording of the session, please contact Dr. Wei Lei (wlei@manchester.edu)